Research
Hormonal
Post-market surveillance is investigating potential links between GLP-1 receptor agonists and suicidal ideation, as well as an increased risk of thyroid cancer of all histologic subtypes.
Stay informed about post-market surveillance findings. The FDA has issued warnings regarding suicidal behavior, and studies suggest a higher risk of thyroid cancer. Discuss these risks with your healthcare provider and follow current evidence-based counseling.
ModerateQualifiesMEDIUM confidence
Regulatory bodies are investigating a possible link between GLP1RAs and suicidal ideation. The United States Food and Drug Administration has a medication guide warning of suicidal behaviour for GLP1RAs. A recent study found a higher risk of thyroid cancer of all histologic subtypes for patients treated with GLP1RAs compared with matched controls.
Why this rating
Based on post-market surveillance and a single cited study, with 'further investigation ongoing'.
Source
Novel obesity treatments
Shohinee Sarma et al. · Canadian Medical Association Journal · 2023
DOI 10.1503/cmaj.230820
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (2.4 mg weekly) combined with intensive behavioral therapy produces significantly greater weight loss (16.0%) and cardiometabolic improvements compared to behavioral therapy alone (5.7%).Strong
- Tirzepatide (5-15 mg weekly) results in significant mean weight loss (15.0-20.9%) and improvements in waist circumference, blood pressure, and lipid levels compared to placebo.Strong
- GLP-1 receptor agonists (Semaglutide and Tirzepatide) are associated with gastrointestinal adverse effects and specific contraindications, including personal or family history of medullary thyroid cancer.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →